In this study, we evaluated the effect of modifying N-linked glycans on recombinant human TPP1 on its pharmacokinetic properties after administration via tail vein injection to a mouse model of LINCL. The gene discussed is TPP1; the disease is late infantile neuronal ceroid lipofuscinosis.